{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:43:58Z","timestamp":1768830238701,"version":"3.49.0"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0006"],"award-info":[{"award-number":["RD16\/0025\/0006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0007"],"award-info":[{"award-number":["RD16\/0025\/0007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI19\/00330"],"award-info":[{"award-number":["FI19\/00330"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP19\/00146"],"award-info":[{"award-number":["CP19\/00146"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>HIV and antiretroviral therapy affect lipid metabolism. Lipidomics quantifies several individual species that are overlooked using conventional biochemical analyses, outperforming traditional risk equations. We aimed to compare the plasma lipidomic profile of HIV patients taking efavirenz (EFV) or rilpivirine (RPV). Patients \u2265 18 years old on EFV co-formulated with emtricitabine and tenofovir disoproxil fumarate (FTC\/TDF) with HIV-RNA &lt; 50 copies\/mL for \u22656 months were randomized to continue EFV\/FTC\/TDF (n = 14) or switch to RPV\/FTC\/TDF (n =15). Lipidomic analyses conducted by mass spectrometry (MS) were performed at baseline and after 12 and 24 weeks. OWLiver\u00ae Care and OWLiver\u00ae tests were performed to estimate the presence of fatty liver disease (NAFLD). No significant differences (83% male, median age 44 years, 6 years receiving EFV\/FTC\/TDF, CD4+ count 740 cells\/mm3, TC 207 [57 HDL-C\/133 LDL-C] mg\/dL, TG 117 mg\/dL) were observed between the groups at baseline. Significant reductions in plasma lipids and lipoproteins but increased circulating bilirubin concentrations were observed in patients who switched to RPV\/FTC\/TDF. Patients on RPV\/FTC\/TDF showed a decrease in the global amount of storage lipids (-0.137 log2 [fold-change] EFV vs. 0.059 log2 [fold-change] RPV) but an increase in lysophosphatidylcholines (LPCs) and total steroids. Compared with EFV, RPV increased metabolites with anti-inflammatory properties and reduced the repository of specific lipotoxic lipids.<\/jats:p>","DOI":"10.3390\/jcm9051246","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:29:15Z","timestamp":1588123755000},"page":"1246","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV\/FTC\/TDF to RPV\/FTC\/TDF: A Randomized Open-Label Trial"],"prefix":"10.3390","volume":"9","author":[{"given":"Adrian","family":"Curran","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rull","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, 43005 Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-0367","authenticated-orcid":false,"given":"Jordi","family":"Navarro","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Vidal-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"},{"name":"Department of Internal Medicine - Hepatology, Hospital Universitari Vall d\u2019Hebron (HUVH), 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Martin-Castillo","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Burgos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9626-0023","authenticated-orcid":false,"given":"Vicen\u00e7","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Torrella","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Planas","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Institut de Recerca (VHIR), 085035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5479","authenticated-orcid":false,"given":"Joaquim","family":"Peraire","sequence":"additional","affiliation":[{"name":"Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, 43005 Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Crespo","sequence":"additional","affiliation":[{"name":"Internal Medicine Department. Complexo Hospitalario Universitario de Vigo; IIS Galicia Sur, 36312 Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"ref_1","first-page":"433","article-title":"All-cause mortality in treated HIV-infected adults with CD4 >=500\/mm3 compared with the general population: Evidence from a large European observational cohort collaboration","volume":"41","author":"Lewden","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e32835cae9c","article-title":"Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population","volume":"27","author":"Rodger","year":"2013","journal-title":"AIDS"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.tcm.2017.06.005","article-title":"Cardiovascular disease in patients with HIV","volume":"27","author":"Ballocca","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cjca.2018.11.029","article-title":"Coronary Artery Disease Manifestations in HIV: What, How, and Why","volume":"35","author":"Sinha","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/eht528","article-title":"HIV infection and cardiovascular disease","volume":"35","author":"Hemkens","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3748\/wjg.v22.i44.9674","article-title":"Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV","volume":"22","author":"Lonardo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sax, P.E., Erlandson, K.M., Lake, J.E., McComsey, G.A., Orkin, C., Esser, S., Brown, T.T., Rockstroh, J.K., Wei, X., and Carter, C.C. (2019). Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin. Infectious Diseases, 1\u201311.","DOI":"10.1093\/cid\/ciz999"},{"key":"ref_8","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2020, March 10). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, Available online: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"ref_9","unstructured":"European AIDS Clinical Society (EACS) guidelines for the Treatment of Adult HIV-Positive Persons (2020, March 10). Version 10.0 November 2019. Available online: https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Activates PXR to Induce Hypercholesterolemia and Hepatic Steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2016.04.028","article-title":"HHS Public AccessMolecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz","volume":"110","author":"Dalwadi","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/jac\/dku262","article-title":"Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: A comparison with efavirenz","volume":"69","author":"Polo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/apc.2013.0310","article-title":"Rilpivirine Versus Efavirenz with Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-Na\u00efve HIV-1\u2013Infected Patients with HIV-1 RNA \u2264100,000 Copies\/mL: Week 96 Pooled ECHO\/THRIVE Subanalysis","volume":"28","author":"Behrens","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciu234","article-title":"Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE trials","volume":"59","author":"Tebas","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15284336.2015.1112480","article-title":"Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia","volume":"17","author":"Thamrongwonglert","year":"2016","journal-title":"HIV Clin. Trials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3268-5","article-title":"Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)","volume":"18","author":"Taramasso","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","article-title":"Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials","volume":"19","author":"Hagins","year":"2018","journal-title":"HIV Med."},{"key":"ref_18","first-page":"1","article-title":"Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction","volume":"9","author":"Wong","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3389\/fimmu.2019.00785","article-title":"Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons","volume":"10","author":"Bowman","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.20411\/pai.v2i3.218","article-title":"Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV","volume":"2","author":"Belury","year":"2017","journal-title":"Pathog. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Trevillyan, J.M., Wong, G., Puls, R., Petoumenos, K., Emery, S., Mellett, N.A., Mundra, P.A., Meikle, P.J., and Hoy, J.F. (2018). Changes in plasma lipidome following initiation of antiretroviral therapy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202944"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jprot.2015.01.019","article-title":"Enhancing metabolomics research through data mining","volume":"127","author":"Mayo","year":"2015","journal-title":"J. Proteom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J. Proteome Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1194\/jlr.E400004-JLR200","article-title":"A Comprehensive Classification System for Lipids","volume":"46","author":"Fahy","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/dom.13285","article-title":"Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus","volume":"20","author":"Bril","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000321","article-title":"Metabolomic signatures associated with disease severity in multiple sclerosis","volume":"4","author":"Villoslada","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Banales, J.M., I\u00f1arrairaegui, M., Arbelaiz, A., Milkiewicz, P., Muntan\u00e9, J., Mu\u00f1oz-Bellvis, L., La Casta, A., Gonzalez, L.M., Arretxe, E., and Alonso, C. (2019). Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 1\u201316.","DOI":"10.1016\/S0618-8278(19)31642-1"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cassol, E., Misra, V., Holman, A., Kamat, A., Morgello, S., and Gabuzda, D. (2013). Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-203"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fernandez, C., Sandin, M., Sampaio, J.L., Almgren, P., Narkiewicz, K., Hoffmann, M., Hedner, T., Wahlstrand, B., Simons, K., and Shevchenko, A. (2013). Plasma Lipid Composition and Risk of Developing Cardiovascular Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071846"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/omi.2016.0178","article-title":"Novel Lipidomic Biomarkers in Hyperlipidemia and Cardiovascular Diseases: An Integrative Biology Analysis","volume":"21","author":"Rai","year":"2017","journal-title":"Omics A J. Integr. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Preuss, C., Jelenik, T., B\u00f3dis, K., M\u00fcssig, K., Burkart, V., Szendroedi, J., Roden, M., and Markgraf, D.F. (2019). A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver. Cells, 8.","DOI":"10.3390\/cells8030277"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Kotronen","year":"2013","journal-title":"Diabetologia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0126910","article-title":"Ceramide as a mediator of non-alcoholic fatty liver disease and associated atherosclerosis","volume":"10","author":"Kasumov","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_35","first-page":"757","article-title":"Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Millan","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2796.2006.01649.x","article-title":"Errors that result from using the TC\/HDL C ratio rather than the apoB\/apoA-I ratio to identify the lipoprotein-related risk of vascular disease","volume":"259","author":"Sniderman","year":"2006","journal-title":"J. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2626-z","article-title":"Cardiovascular risk and dyslipidemia among persons living with HIV: A review","volume":"17","author":"Maggi","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0193041","article-title":"Relationship between serum bilirubin levels and cardiovascular disease","volume":"13","author":"Suh","year":"2018","journal-title":"PLoS ONE"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.mehy.2015.10.013","article-title":"Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis","volume":"85","author":"Akerele","year":"2015","journal-title":"Med. Hypotheses"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Law, S.H., Chan, M.L., Marathe, G.K., Parveen, F., Chen, C.H., and Ke, L.Y. (2019). An updated review of lysophosphatidylcholine metabolism in human diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051149"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1161\/01.ATV.20.12.2614","article-title":"Plasma sphingomyelin level as a risk factor for coronary artery disease","volume":"20","author":"Jiang","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/eurheartj\/ehz387","article-title":"Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients","volume":"441","author":"Hilvo","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000362736","article-title":"Stress, the stress system and the role of glucocorticoids","volume":"22","author":"Nicolaides","year":"2014","journal-title":"NeuroImmunoModulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"ref_45","first-page":"3925","article-title":"Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice","volume":"159","author":"Koorneef","year":"2018","journal-title":"Endocrinology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:51:17Z","timestamp":1760363477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/5\/1246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["jcm9051246"],"URL":"https:\/\/doi.org\/10.3390\/jcm9051246","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,25]]}}}